AC2993 LAR: AMLN started a double-blind, placebo-controlled U.S. Phase II trial of AC2993 LAR in up to 100 patients to treat Type II diabetes. AC2993 LAR uses M

Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif.
Product: AC2993 LAR
Business: Metabolic
Therapeutic

Read the full 132 word article

How to gain access

Continue reading with a
two-week free trial.